RxDoctor Payments Data

Jacqueline Schwartz, MD

Clinical Cardiac Electrophysiology · Los Angeles, CANPI 1235436924

Payments from drug & device makers

$46,036in general payments, 2019–2025

Across 286 payments — averaging $160.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$20K
  • Boston Scientific$20K
  • Medtronic$3K
  • Biosense Webster, Inc.$771
  • Cvrx, Inc.$419
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$227
  • plus $1K from 14 others

What the payments were for

  • Consulting fees$2,07511%
  • Travel & lodging$3,34818%
  • Food & beverage$13,64172%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$46,036 in reported general payments places this provider in the 55th percentile of 290 clinical cardiac electrophysiology providers in California.

See all clinical cardiac electrophysiology providers in California

Medicare billing

Part B allowed, 2024
$584,111
Medicare patients
951
Services billed
6,612

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban526$612,681
XareltoRivaroxaban227$263,271
MultaqDronedarone Hcl11$14,369
EntrestoSacubitril/Valsartan13$13,007
Metoprolol Succinate658$11,871
Propafenone Hcl ErPropafenone Hcl53$10,795
Flecainide Acetate277$9,105
SotalolSotalol Hcl449$8,576
Amiodarone Hcl157$3,922
ClopidogrelClopidogrel Bisulfate181$2,217
Dilt-XrDiltiazem Hcl41$1,704
Propafenone Hcl20$1,210
Diltiazem 24hr Er (Cd)Diltiazem Hcl31$852
Carvedilol111$652
Metoprolol Tartrate70$584

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$110$612,681526 claims
Johnson & JohnsonXarelto$141$263,271227 claims
NovartisEntresto$32$13,00713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 290 clinical cardiac electrophysiology providers in California.

Other clinical cardiac electrophysiology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →